CLCP1 inhibitors, also known as Cullin-RING Ligase Complex-Associated Protein 1 inhibitors, constitute a diverse class of chemical compounds designed to target a specific protein within the cellular ubiquitin-proteasome system. CLCP1 is an essential component of the NEDDylation pathway, a post-translational modification process crucial for regulating protein degradation within the cell. Inhibition of CLCP1 leads to disruption of the NEDDylation cascade, ultimately affecting the activity of Cullin-RING E3 ligases (CRLs). This class of inhibitors has gained significant attention in the realm of cellular biology and drug discovery due to their ability to manipulate protein degradation pathways, offering insights into cellular regulation and the development of novel interventions.
The mechanism of action of CLCP1 inhibitors primarily centers on disrupting the NEDDylation process, which involves the attachment of the small ubiquitin-like modifier NEDD8 to target proteins. CLCP1 acts as a key player in this pathway by catalyzing the NEDD8 transfer to Cullin subunits within CRLs, a vital step for their activation. By selectively inhibiting CLCP1, these compounds hinder NEDDylation, subsequently causing the inactivation of CRLs. This leads to the accumulation of CRL substrates, which are typically targeted for ubiquitination and subsequent proteasomal degradation. Consequently, CLCP1 inhibitors trigger the stabilization of these substrates, impacting various cellular processes dependent on CRL-mediated protein turnover, such as cell cycle regulation, DNA repair, and response to cellular stress.In summary, CLCP1 inhibitors represent a burgeoning class of chemical compounds with a well-defined mechanism of action focused on disrupting the NEDDylation pathway. Their ability to modulate the cellular ubiquitin-proteasome system through targeted inhibition of CLCP1 offers valuable insights into fundamental cellular processes and holds promise for furthering our understanding of protein degradation pathways in health and disease. These inhibitors serve as valuable tools for elucidating cellular biology and may have applications in various fields beyond their current research-focused use.
SEE ALSO...
Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
---|---|---|---|---|---|---|
MLN7243 | 1450833-55-2 | sc-507338 | 5 mg | $340.00 | ||
TAK-243 inhibits CLCP1 by binding to the active site and blocking the activation of Cullin-RING E3 ligases (CRLs). This leads to the accumulation of CRL substrates, inducing cell cycle arrest and apoptosis in cancer cells. | ||||||
MLN 4924 | 905579-51-3 | sc-484814 | 1 mg | $280.00 | 1 | |
MLN4924 inhibits CLCP1 by blocking NEDDylation, a critical step in CRL activation. This results in the stabilization of CRL substrates, promoting apoptosis and inhibiting tumor growth. | ||||||
FK-866 | 658084-64-1 | sc-205325 sc-205325A | 5 mg 10 mg | $140.00 $245.00 | 12 | |
APO866 inhibits CLCP1 by targeting NAD+ biosynthesis, depleting cellular NAD+ levels. This impairs DNA repair mechanisms and induces apoptosis in cancer cells. |